Noxopharm Ltd has released a press release.
NOX announces Positive Data from CEP-1 Study of Veyonda
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- NOX to Present Clinical Data at COSA Annual Meeting
- Appendix 4C - quarterly
- Change of Registry Address: Automic P/L - Sydney Office
- NOX Subsidiary Announces Important Drug Discovery
- NOX to support expanded LuPIN study
Later from Noxopharm
- DARRT-1 study advancing on basis of positive clinical data
- NOX Receives $3.26M Federal Govt R&D Rebate
- Principal Investigator Discusses LuPIN-1 Study
- Veyonda and Radiotherapy Delivers Clinical Benefits
- FNN interview with Nox Chief Medical Officer on Interim Data
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm